Drugs / TolaSure
TolaSure
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT03620175 Comparator | Jul → Dec 2018 | — | BioMendics, LLC | Completed | No outcome recorded |
| Phase 2 | NCT07027345 Comparator | Sep → Dec 2025 overdue | epidermolysis bullosa simplex | BioMendics, LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT04088357 Comparator | Aug 2019 → Apr 2020 | — | BioMendics, LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TolaSure | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07027345 ↗ |
| Known as | TolaSure Gel | “topical TolaSure Gel, 5% w/w” NCT07027345 ↗ |
| Known as | TolaSure Topical Gel | “Drug: TolaSure Topical Gel” NCT04088357 ↗1“5% TolaSure Topical Gel” NCT07027345 ↗ |
| Route | Topical | “TolaSure topical gel is applied to skin punch biopsies daily over the course of 2 weeks.” NCT03620175 ↗ |